What causes brain cell death in Parkinson’s patients
January 8th, 2011 - 5:10 pm ICT by ANIWashington, Jan 08 (ANI): Researchers at The University of Texas Health Science Center have discovered a process that may begin to explain why the vast majority of Parkinson’s patients develop the progressive neurodegenerative disease.
The researchers demystified a process that leads to the death of brain cells - or neurons - in Parkinson’s patients. When researchers blocked the process, the neurons survived.
The findings could lead to an effective treatment to slow the progression of Parkinson’s disease, rather than simply address symptoms that include tremors, slowed movement, muscle stiffness and impaired balance. Further studies could lead to a diagnostic test that could screen for Parkinson’s years before symptoms develop, said Syed Z. Imam, adjunct assistant professor at the UT Health Science Center.
After analyzing cells and post-mortem brain tissue from animals and humans, researchers noted that oxidative stress - a known culprit in neuron death - activated a protein called tyrosine kinase c-Abl in the nigra-striatum area of the brain. Neurons in this part of the brain are particularly vulnerable to Parkinson’s injury.
Activation of this protein led to changes in another protein called parkin, which is known to be mutated in hereditary Parkinson’s. The altered parkin lacked the capacity to break down other proteins, leading to harmful clumps of unprocessed protein in the neuron. The scientists believe this accumulation leads to progressive neuron death, resulting in Parkinson’s symptoms that worsen over time.
“When we blocked tyrosine kinase c-Abl activation, parkin function was preserved and neurons were spared,” Imam said.
“We believe these studies provide sound rationale for moving forward with a preclinical trial of tyrosine kinase c-Abl inhibitors, with the goal of developing a potent therapeutic drug for slowing the progression of Parkinson’s.”
If preclinical trials in animal models of Parkinson’s disease yield positive results, the next step would be clinical trials in human patients, Imam said.
“The race is on to understand the mechanism of the 95 percent of Parkinson’s cases with no known cause, and our finding certainly is a building block,” Imam said.
“We have found a specific signaling mechanism that is only turned on by oxidative stress and is selective only to Parkinson’s-affected neurons of the nigra-striatum, which is the area that sends signals for balance to the cerebellum,” Imam added.
The study has been published in the Journal of Neuroscience. (ANI)
- Toxin that plays key role in triggering Parkinson's disease identified - Feb 11, 2011
- Premature death of brain neurons 'may trigger Parkinson's' - Nov 11, 2010
- Excess of protein used as anti-cancer drug triggers Parkinson's disease - Oct 02, 2010
- Two genes tell how Parkinson's progresses - Feb 13, 2012
- 'Key player' that facilitates Parkinson's disease found - Mar 04, 2011
- Study provides new insight into Parkinson's disease - Apr 05, 2011
- Drug that stops progression of Parkinson's disease in mice found - Mar 09, 2011
- Naturally occurring brain mechanism ups Parkinson's understanding - Feb 12, 2011
- Scientists produce compound that may treat Parkinson's disease - Feb 12, 2011
- Novel molecular pathway underlying Parkinson's disease identified - Sep 14, 2010
- Scientists identify 'molecule trio' that kills neurons in Parkinson's - Apr 30, 2009
- Vitamin K2 found promising in Parkinson's treatment - May 13, 2012
- Protein pathway find may help solve Parkinson's disease - Mar 01, 2011
- New model paves way for drugs to fight Parkinson's disease - Feb 02, 2011
- Novel gene therapy shows promise against Alzheimer's - Mar 05, 2011
Tags: address symptoms, adjunct assistant professor, animal models, brain cell death, brain cells, brain neurons, brain tissue, health science center, muscle stiffness, neurodegenerative disease, neuron death, preclinical trial, preclinical trials, sound rationale, texas health science, texas health science center, therapeutic drug, tyrosine kinase, university of texas health science center, ut health science center